Showing results (391-400 of 538) with videos related to

Sort By:
Pageof 54
The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.
Annals of the Rheumatic Diseases|March 8, 2011
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisMaya H Buch, Josef S Smolen, Neil Betteridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 25, 2024
Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological DataYann Nguyen, Maxime Beydon, Jacques-Eric Gottenberg, et al.
RMD Open|October 2, 2024
Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sjögren's diseaseLaurie Georgel, Anas-Alexis Benyoussef, Sofian Berrouiguet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Annals of the Rheumatic Diseases|June 7, 2020
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2Robert Bm Landewé, Pedro M Machado, Féline Kroon, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|August 12, 2020
Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESSRenaud Felten, Margherita Giannini, Benoit Nespola, et al.
Lancet (London, England)|August 3, 2024
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyBenjamin A Fisher, Xavier Mariette, Athena Papas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2023
Liposomal AntagomiR-155-5p Restores Anti-Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid ArthritisAudrey Paoletti, Bineta Ly, Catherine Cailleau, et al.
Pageof 54